The North America Multiple Myeloma Market would witness market growth of 8.6% CAGR during the forecast period (2023-2029).
The increased prevalence of multiple myeloma, an increase in the number of market players who produce multiple myeloma pharmaceuticals, and an increase in the number of product releases for multiple myeloma drugs are the main factors driving the growth of the market. Multiple myeloma is often called Kahler's disease. The blood and bones were exposed to excessive protein. Organ damage results from its accumulation throughout the body.
One of the main types of blood cancer that accounts for a sizable portion of cases of cancer is multiple myeloma (MM), despite being regarded as an uncommon form of cancer. More patients are diagnosed with their ailment due to growing awareness of disease signs. Increased treatment sophistication by key market players has resulted in several successful and potentially successful medications being released. In diagnosed patients, death could result from untreated conditions. Due to unmet clinical requirements and the growing demand for effective treatment outcomes, market players are conducting a large number of clinical studies for the introduction of new therapies.
According to the International Agency for Research on Cancer, there were 35318 new cases of multiple myeloma registered in the region in 2020. According to the American Cancer Society, the US saw almost 24,050 new instances of multiple myeloma at the end of 2014. In this region, age-related increases in the frequency of multiple myelomas are more common in males than women. Thus, a rise in the older population would surely fuel the demand for therapies for multiple myeloma. Thus, the important factors anticipated to accelerate the expansion of the market for multiple myeloma are the increasing occurrence of the condition and the rise in the senior population. Thus, the market in the North America will increase significantly in the coming years.
The US market dominated the North America Multiple Myeloma Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $10,505.2 Million by 2029. The Canada market is poised to grow at a CAGR of 10.7% during (2023 - 2029). Additionally, The Mexico market would witness a CAGR of 10.4% during (2023 - 2029).
Based on End User, the market is segmented into Hospitals, Clinics, and Others. Based on Disease Type, the market is segmented into Active Multiple Myeloma and Smoldering Multiple Myeloma. Based on Drug Type, the market is segmented into Protease Inhibitors, Monoclonal Antibody, Chemotherapy and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Multiple Myeloma Market is Projected to reach USD 37.5 Billion by 2029, at a CAGR of 9.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Bristol Myers Squibb Company, Amgen, Inc., AbbVie, Inc., Sanofi S.A., Johnson & Johnson, Baxter International, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., and Pfizer, Inc.
Scope of the Study
Market Segments Covered in the Report:
By End User
By Disease Type
- Active Multiple Myeloma
- Smoldering Multiple Myeloma
By Drug Type
- Protease Inhibitors
- Monoclonal Antibody
- Chemotherapy
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- Bristol Myers Squibb Company
- Amgen, Inc.
- AbbVie, Inc.
- Sanofi S.A.
- Johnson & Johnson
- Baxter International, Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries Ltd.
- Pfizer, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Multiple Myeloma Market, by End User
1.4.2 North America Multiple Myeloma Market, by Disease Type
1.4.3 North America Multiple Myeloma Market, by Drug Type
1.4.4 North America Multiple Myeloma Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Trials and Approvals
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. North America Multiple Myeloma Market by End User
4.1 North America Hospitals Market by Country
4.2 North America Clinics Market by Country
4.3 North America Others Market by Country
Chapter 5. North America Multiple Myeloma Market by Disease Type
5.1 North America Active Multiple Myeloma Market by Country
5.2 North America Smoldering Multiple Myeloma Market by Country
Chapter 6. North America Multiple Myeloma Market by Drug Type
6.1 North America Protease Inhibitors Market by Country
6.2 North America Monoclonal Antibody Market by Country
6.3 North America Chemotherapy Market by Country
6.4 North America Others Market by Country
Chapter 7. North America Multiple Myeloma Market by Country
7.1 US Multiple Myeloma Market
7.1.1 US Multiple Myeloma Market by End User
7.1.2 US Multiple Myeloma Market by Disease Type
7.1.3 US Multiple Myeloma Market by Drug Type
7.2 Canada Multiple Myeloma Market
7.2.1 Canada Multiple Myeloma Market by End User
7.2.2 Canada Multiple Myeloma Market by Disease Type
7.2.3 Canada Multiple Myeloma Market by Drug Type
7.3 Mexico Multiple Myeloma Market
7.3.1 Mexico Multiple Myeloma Market by End User
7.3.2 Mexico Multiple Myeloma Market by Disease Type
7.3.3 Mexico Multiple Myeloma Market by Drug Type
7.4 Rest of North America Multiple Myeloma Market
7.4.1 Rest of North America Multiple Myeloma Market by End User
7.4.2 Rest of North America Multiple Myeloma Market by Disease Type
7.4.3 Rest of North America Multiple Myeloma Market by Drug Type
Chapter 8. Company Profiles
8.1 Johnson & Johnson
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental &Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Trials and Approvals:
8.1.5.2 Acquisition and Mergers:
8.1.6 SWOT Analysis
8.2 Novartis AG
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Product Launches and Product Expansions:
8.3 Sanofi S.A.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Trials and Approvals:
8.4 Amgen, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Trials and Approvals:
8.4.5.2 Acquisition and Mergers:
8.5 AbbVie, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.6 Baxter International, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Acquisition and Mergers:
8.7 Teva Pharmaceutical Industries Ltd.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Product Launches and Product Expansions:
8.8 Pfizer, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional & Segmental Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Acquisition and Mergers:
8.9 Bristol Myers Squibb Company
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 Recent strategies and developments:
8.9.5.1 Trials and Approvals:
8.9.5.2 Acquisition and Mergers:
8.10. Takeda Pharmaceutical Company Limited
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expense
TABLE 1 North America Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 2 North America Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Multiple Myeloma Market
TABLE 4 Product Launches And Product Expansions– Multiple Myeloma Market
TABLE 5 Acquisition and Mergers– Multiple Myeloma Market
TABLE 6 Trials and approvals – Multiple Myeloma Market
TABLE 7 North America Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 8 North America Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 9 North America Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 10 North America Hospitals Market by Country, 2023 - 2029, USD Million
TABLE 11 North America Clinics Market by Country, 2019 - 2022, USD Million
TABLE 12 North America Clinics Market by Country, 2023 - 2029, USD Million
TABLE 13 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 14 North America Others Market by Country, 2023 - 2029, USD Million
TABLE 15 North America Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 16 North America Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 17 North America Active Multiple Myeloma Market by Country, 2019 - 2022, USD Million
TABLE 18 North America Active Multiple Myeloma Market by Country, 2023 - 2029, USD Million
TABLE 19 North America Smoldering Multiple Myeloma Market by Country, 2019 - 2022, USD Million
TABLE 20 North America Smoldering Multiple Myeloma Market by Country, 2023 - 2029, USD Million
TABLE 21 North America Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 22 North America Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 23 North America Protease Inhibitors Market by Country, 2019 - 2022, USD Million
TABLE 24 North America Protease Inhibitors Market by Country, 2023 - 2029, USD Million
TABLE 25 North America Monoclonal Antibody Market by Country, 2019 - 2022, USD Million
TABLE 26 North America Monoclonal Antibody Market by Country, 2023 - 2029, USD Million
TABLE 27 North America Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 28 North America Chemotherapy Market by Country, 2023 - 2029, USD Million
TABLE 29 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 30 North America Others Market by Country, 2023 - 2029, USD Million
TABLE 31 North America Multiple Myeloma Market by Country, 2019 - 2022, USD Million
TABLE 32 North America Multiple Myeloma Market by Country, 2023 - 2029, USD Million
TABLE 33 US Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 34 US Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 35 US Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 36 US Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 37 US Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 38 US Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 39 US Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 40 US Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 41 Canada Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 42 Canada Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 43 Canada Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 44 Canada Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 45 Canada Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 46 Canada Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 47 Canada Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 48 Canada Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 49 Mexico Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 50 Mexico Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 51 Mexico Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 52 Mexico Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 53 Mexico Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 54 Mexico Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 55 Mexico Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 56 Mexico Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 57 Rest of North America Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 58 Rest of North America Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 59 Rest of North America Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 60 Rest of North America Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 61 Rest of North America Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 62 Rest of North America Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 63 Rest of North America Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 64 Rest of North America Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 65 Key information –Johnson & Johnson
TABLE 66 Key Information – Novartis AG
TABLE 67 Key Information – Sanofi S.A.
TABLE 68 Key Information – Amgen, Inc.
TABLE 69 Key information – AbbVie, Inc.
TABLE 70 Key Information – Baxter International, Inc.
TABLE 71 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 72 Key Information – Pfizer, Inc.
TABLE 73 Key Information – Bristol Myers Squibb Company
TABLE 74 Key Information – Takeda Pharmaceutical Company Limited
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 SWOT analysis: Johnson & Johnson
FIG 5 Recent strategies and developments: Novartis AG
FIG 6 Recent strategies and developments: Sanofi S.A.